



# Trajectories of Adherence to Low-Dose Aspirin Treatment Among the French Population

Aya Ajrouche, Candice Estellat, Yann de Rycke, Florence Tubach

## ► To cite this version:

Aya Ajrouche, Candice Estellat, Yann de Rycke, Florence Tubach. Trajectories of Adherence to Low-Dose Aspirin Treatment Among the French Population. *Journal of Cardiovascular Pharmacology and Therapeutics*, In press, 10.1177/1074248419865287 . hal-02284218

**HAL Id: hal-02284218**

**<https://hal.sorbonne-universite.fr/hal-02284218>**

Submitted on 11 Sep 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Title page**

**Trajectories of adherence to low-dose aspirin treatment among the French population**

**Running title: Adherence to low-dose aspirin in France**

A. Ajrouche<sup>1</sup>, C. Estellat<sup>1</sup>, Y. De Rycke<sup>1</sup>, F. Tubach<sup>1</sup>

<sup>1</sup>Sorbonne Université, Faculté de médecine Sorbonne Université, AP-HP, Hôpital Pitié-Salpêtrière, Département Biostatistique Santé Publique et Information Médicale, Centre de Pharmacoépidémiologie (Cephepi), INSERM, UMR 1123, ECEVE, CIC-P 1421, F-75013 Paris, France

**Word count:** 5,289 (including Abstract, Figure Legends and References)

**Correspondence To:**

Pr Florence Tubach, Département Biostatistique Santé Publique et Information Médicale, Hôpital Pitié Salpêtrière, 47-83 Bd de l'Hôpital, 75013 Paris, France.

E-mail: [florence.tubach@aphp.fr](mailto:florence.tubach@aphp.fr)

**Submission Declaration:**

This manuscript is an original work that has not been published and is not under consideration for publication elsewhere.

**Sources of Funding :**

This work was supported by a research grant from the French ministry of health [Grant number PHRC-K 14-158]; by an academic grant from Paris Diderot University-Sorbonne Paris Cité [No grant number is applicable] to A.A.

**Disclosures :**

The pharmacoepidemiology and clinical research unit (FT, CE, YD) has received research funding, grants and fees for consultant activities that have contributed indiscriminately to the salaries of its employees.

**KEYWORDS:** aspirin; adherence; Group-based trajectory modeling; SNDS; pharmacoepidemiology. population-based study

## 1    **Abstract**

## 2    **Background**

3    Previous studies have shown that adherence to low-dose aspirin is suboptimal.  
4    However, these studies were based on an average measure of adherence during follow-  
5    up, ignoring its dynamic process over time. We described the trajectories of adherence to  
6    low-dose aspirin (LDA) treatment among the French population over 3 years of follow-  
7    up.

## 8    **Methods**

9    We identified a cohort of 11,793 new LDA users, aged  $\geq 50$  years in 2010, by using the  
10   French national healthcare database. Patients included had at least 3 years of history in  
11   the database before study entry to exclude prevalent aspirin users and to assess  
12   baseline comorbidities. They were followed from the first date of LDA supply (the index  
13   date) until the first date among death, exit from the database, or 3 years after the index  
14   date. LDA adherence was assessed every 3 months by using the proportion of days  
15   covered (PDC) and dichotomized with a cutoff of PDC of 0.8. We used group-based  
16   trajectory modeling to identify trajectories of LDA adherence. Predictors of LDA  
17   adherence trajectory membership were identified by multinomial logistics regression.

## 18   **Results**

19   We identified four trajectories of adherence among new LDA users: the not-adherents  
20   (4737 [40.2%]), the delayed not-adherents (gradual decrease in adherence probability;  
21   1601 [13.6%]), the delayed adherents (gradual increase in adherence probability; 1137

[9.6%]) and the persistent adherents (4318 [36.6%]). The probability of belonging to the not adherent group was increased with female sex, low socioeconomic status and polymedication and was reduced with a secondary indication for LDA use, diabetes, hypertension, dementia, at least 4 consultations in the previous year, or one hospitalization or a cardiologist consultation in the 3 months before the index date.

## **Conclusion**

This study provides a dynamic picture of adherence behaviors among new LDA users and underlines the presence of critical trajectories that intervention could target to improve adherence.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

## 1 Introduction

2 Cardiovascular diseases are the leading cause of death worldwide, accounting for  
3 31% of all global deaths<sup>1</sup>. To prevent cardiovascular morbidity and mortality, low-dose  
4 aspirin (LDA) treatment is among the most widely used<sup>2,3</sup>. Its efficacy in the secondary  
5 prevention of cardiovascular disease has been established: the benefits in reducing  
6 cardiovascular events outweighs the risk of hemorrhage<sup>4</sup>. However, its efficacy in  
7 primary prevention is more controversial, with recent published trials that did not support  
8 its use<sup>3,5</sup> and conflicting guidelines between American and European societies<sup>6-9</sup>. Many  
9 American societies recommended low dose aspirin in the primary prevention settings,  
10 among subjects aged 50 years or more<sup>6,7,10-12</sup>, but European guidelines were more  
11 cautious because of the associated risk of bleeding<sup>13</sup>, however, in 2014 a position paper  
12 of the European Society of Cardiology suggested that aspirin might be considered in the  
13 primary prevention of CVD in both sexes at a high risk of major cardiovascular events,  
14 and no increased risk of bleeding. As for French recommendation, the French national  
15 authority of health recommended in a paper in 2012 aspirin in the primary prevention  
16 among subject with a high cardiovascular risk<sup>14</sup>.

17 To achieve optimal efficacy, LDA must be taken daily and maintained  
18 indefinitely<sup>15,16</sup>. Still, previous studies have shown that adherence to LDA is  
19 suboptimal<sup>17,18</sup>, with the lowest rates among all cardiovascular preventive therapies  
20 (65%)<sup>17</sup>. Consequences of this poor adherence are decreased treatment effectiveness  
21 and increased cardiovascular morbidity and mortality<sup>19-21</sup>. Poor adherence is complex,  
22 given its multifactorial nature<sup>22</sup>, and needs to be well understood and described to be  
23 better managed.

1 With the advent of medico-administrative databases, drug adherence has been  
2 extensively described in studies using these databases. However, many of these studies  
3 were based on an average measure of adherence during follow-up<sup>23–27</sup>, ignoring its  
4 dynamic process over time. Actually, individuals with similar average measures of  
5 adherence may show different profiles of adherence evolution during follow-up. We  
6 addressed this limitation by applying another approach, group-based trajectory modeling  
7 (GBTM), that identifies the presence of latent groups of individuals sharing similar  
8 evolution of an outcome of interest during follow-up<sup>28</sup>. These models were first  
9 developed in the context of sociological and behavioural research to identify subgroups  
10 of individuals showing different trajectories of outcome<sup>28</sup>. However, several studies have  
11 recently applied them in the context of adherence to medications<sup>29–32</sup>, to clusters  
12 individuals with similar trajectories of adherence over time and explore predictors of  
13 each trajectory.

14 Therefore, the main objective of this study was to describe the trajectories of LDA  
15 use among the French population in the primary and secondary prevention settings and  
16 over 3 years of follow-up. Secondary objectives were to 1) describe the trajectories of  
17 LDA use according to the presence or not of a secondary indication for LDA use  
18 according and 2) identify predictors of LDA adherence trajectory.

## 19 **Methods**

### 20 *Data source*

21 The *Système National des Données de Santé* (SNDS) is the French national  
22 healthcare database that contains prospectively recorded data on all beneficiaries'

1 medical reimbursements covered by the different health insurance schemes: the general  
2 scheme covers about 86% of France residents, and 14 other schemes cover the rest<sup>33</sup>.  
3 It contains information on beneficiaries' age, sex, date of death, Complementary  
4 Universal Health Coverage (CMU-C) status and all outpatient health-care consumption  
5 including all reimbursed prescription drugs coded according to the Anatomical  
6 Therapeutic Chemical (ATC) classification system<sup>34</sup>, the date of delivery, quantity, and  
7 brand name. It also contains the long-term chronic disease (LTD) status, allowing for full  
8 medical reimbursement; the date of the LTD diagnosis; and its nature, coded according  
9 to the International Classification of Diseases, 10<sup>th</sup> revision (ICD-10)<sup>35</sup>. Through the  
10 *Programme de Médicalisation des Systèmes d'Information* (PMSI), the SNDS also  
11 includes medical summaries of all hospitalizations, including the date of stay, medical  
12 procedures and expensive drugs during the hospital stay, the primary diagnosis (main  
13 reason for admission), related diagnoses (specifies the disease context of the primary  
14 diagnosis) and diagnoses related to other comorbidities, all encoded according to the  
15 ICD-10.

16 In this study, we used the *Echantillon Généraliste de Bénéficiaires* (EGB)  
17 database, which is a 1/97th dynamic random sample of the SNDS, containing the same  
18 data, and more easily available for researchers<sup>33</sup>.

### 19 *Study design and follow up*

20 This was a historical cohort study to identify and describe trajectories of LDA use  
21 among the French population during 3 years of follow-up. The index date was the first  
22 LDA delivery between January 1, 2010 and December 31, 2012. All individuals were

1 then followed from the index date to the earliest of death from any cause, exit from the  
2 database or month 36 after the first LDA delivery.

### 3 *Study population*

4 All individuals in the EGB sample covered by the French national general health  
5 insurance scheme since January 1, 2007 and who were at least 50 years old on January  
6 1, 2010 were eligible for inclusion. We restricted our study population to the general  
7 health insurance scheme because only these data were available since 2007. We  
8 required at least 3 years of history in the database between January 1, 2007 and  
9 January 1, 2010 to exclude prevalent LDA users defined by at least one LDA delivery in  
10 this 3-year period and to assess baseline characteristics and comorbidities. We also  
11 required at least 3 months of follow-up after the index date to have at least one  
12 adherence measure during follow-up.

### 13 *Definition of LDA adherence*

14 We selected all reimbursed drugs with ATC codes corresponding to an aspirin  
15 dose of 50 to 325 mg (the antiplatelet dose). The definition of adherence was based on  
16 the proportion of days covered (PDC) according to the Centers for Medicare and  
17 Medicaid Services method<sup>36</sup>. This method allows for calculating adherence to a  
18 treatment over a given period, taking into account hospitalizations during each  
19 assessment period and the overlap between 2 deliveries. After the first aspirin delivery,  
20 we calculated a PDC for each 3 calendar months until the end of follow-up by dividing  
21 the number of days covered with aspirin treatment delivered over the previous 90 days  
22 by 90. However, if any hospitalization occurred during the assessment period, we

excluded the total number of hospital days from the PDC calculation ( by dividing the number of non-hospital days covered with aspirin treatment delivered over the previous 90 days by the total number of non-hospital days). As recommended, good adherence was defined as  $PDC \geq 0.8$  and poor adherence otherwise<sup>37,38</sup>. In a sensitivity analysis, we also considered an alternative cutoff of 0.5 to define good adherence to account for OTC use among LDA users. PDC for Individuals who died or exit database were considered missing after the date of exit from the database or death.

### *Covariates*

We considered the following covariates for describing individuals and multivariate adjustment:

*Cardiovascular risk* factors included age, sex, morbid obesity (defined by bariatric surgery or hospitalization related to obesity), heavy alcoholism (defined by alcoholic liver cirrhosis or hospitalization related to alcohol use disorder), smoking-related conditions (defined by chronic obstructive pulmonary disease or hospitalization related to smoking-related disorder), diabetes, hypertension and dyslipidemia.

*Indications advocating secondary prevention treatment with LDA* were defined at baseline in the 3-year period before the index date and included coronary heart disease (coronary artery disease, unstable angina, myocardial infarction, history of coronary artery bypass grafting or percutaneous coronary intervention), stroke or transient ischemic attack, peripheral artery disease (atherosclerosis or obstructive arteriopathy of lower limbs), atrial fibrillation or bioprosthetic or mechanical valvular replacement surgery.

1            *Other comorbidities of interest* were psychiatric disorder, dementia, end-stage  
2 chronic renal failure, cancer and major hemorrhagic events.

3            *Low socioeconomic status*, defined by the Complementary Universal Health  
4 Coverage (CMU-C, a free complementary health insurance for individuals of low  
5 socioeconomic status).

6            All these previous covariates were defined at baseline in the 3-year period  
7 before the index date.

8            *Health-seeking behavior* was addressed by the proxy number of physician visits  
9 and polymedication by the number of distinct ATC classes delivered per year (assessed  
10 during the year before the index date). We also considered the presence of at least one  
11 hospitalization or a cardiologist consultation during the 3 months before the index date.

12            *Co-treatments* were other antithrombotics including non-aspirin antiplatelets  
13 and anticoagulants, each defined by reimbursement for one of these therapies during  
14 each assessment period.

15            The occurrence of acute coronary events, acute stroke, transient ischemic  
16 attack, or major hemorrhagic events was described during follow-up.

17            Previously developed algorithms were used to define each indication or co-  
18 morbidity and combined information from drug reimbursements, medical procedures  
19 (CCAM), hospital and LTD diagnosis<sup>39,40</sup>. Supplemental codes of identification for  
20 comorbidities are presented in the supplemental material.

21  
22            *Statistical analysis (more details available in supplemental material)*

23            Group Based trajectory models

1 GBTM is a semi-parametric mixture model that captures the heterogeneity in a  
2 population by clustering individuals following distinct trajectories of adherence into  
3 different group<sup>28</sup>. We applied this model using proc traj, a SAS macro for GBTM<sup>41,42</sup> that  
4 allows comparing different models with several pre-specified number of groups (one to  
5 five groups). Each model predicted the probability of belonging to each group, then  
6 assigned the individual to the group for which the participant had the highest probability  
7 of belonging. The selection of the optimal model was based on the lowest value of the  
8 Bayesian Information Criterion (BIC), a minimum number of individuals allocated to each  
9 trajectory of 5%, a minimum average probability of being assigned to a group of 70%, a  
10 minimum entropy of 0.7 (a discrimination measure to aid in determining how well  
11 individuals are classified into their groups; the nearest this measure is to 1, the better  
12 the individuals are classified<sup>43</sup>) and the clinical relevance of the model.

### 13 Predictors of adherence group

14 Once the optimal model was selected, we described baseline characteristics  
15 between the different groups with median (interquartile range [IQR]) for continuous  
16 variables and frequency (%) for categorical variables by trajectory. We then identified  
17 baseline predictors of belonging to each trajectory by multinomial (logit) regression  
18 analysis, considering the high adherence group as the reference. Odds ratios (ORs) and  
19 95% confidence intervals (CIs) were calculated. Polymedication was classified in 3  
20 classes ( $\leq 10$ , 11-20,  $\geq 21$ ) and number of consultations per year in 4 classes ( $\leq 3$ , 4-6,  
21 7-12,  $> 13$ ). Predictive accuracy of the model was tested with C-statistics.

### 23 Secondary analysis

For secondary analyses, first the same trajectory modeling analysis was repeated to identify the trajectory of adherence for individuals with and without a secondary prevention indication for LDA at baseline. Second, we described the presence of co-treatment with antithrombotics (anticoagulants or antiplatelets) as well as the occurrence of thromboembolic and major hemorrhagic events during follow-up by each adherence group.

Finally, in a sensitivity analysis, we considered first an alternative cutoff of 0.5 for PDC calculation and second, included only individuals without any missing PDC values during follow-up (N=10,416) (i.e., death or exit from the database before month 36, hospitalization period longer than 3 months), to test for the impact of missing data on the results.

All analyses were performed with SAS Enterprise Guide V.7.1.  $P < 0.05$  was considered statistically significant.

## **Results**

### **Study population**

We included 5,853 men and 5,940 women with a first LDA delivery between January 1, 2010 and December 31, 2012 (Figure 1). The median (IQR) age at inclusion was 69.0 [61.0-79.0] years (Table 1) and median follow-up 36 months. Only one-third of the study population had a secondary prevention indication for LDA at baseline [coronary heart disease (17.8%) and/or stroke or transient ischemic attack (6.9%) and/or peripheral artery disease (13.5%) and/or atrial fibrillation (9.1%) and/or bioprosthetic or mechanical valvular replacement surgery (0.7%)]. During follow-up, we observed 1,293 deaths (11%) and 81 exits from the database (0.7%) (Table 2).

## Identification and characteristics of trajectories

We identified 4 trajectories of adherence among new LDA users (Figure 2): the not-adherent group (40.2% of the study population), the delayed not-adherent group (who showed a high probability of being adherent at the beginning of follow-up but gradually decreasing probabilities during follow-up; 13.6% of the study population); the delayed adherent group (who showed a low probability of being adherent during the first 12 months of follow-up and then their probability of adherence increased gradually thereafter; 9.6% of the study population) and the persistent adherent group (36.6% of the study population). Characteristics of these 4 groups are in Table 1. During follow-up, the delayed not-adherent group showed increased frequency of major hemorrhagic events (Table 2) and a gradual increase in antithrombotic treatment during follow-up (Figure S1), mainly due to a gradual increase in anticoagulant treatment (Figure S2). Individuals in the delayed adherent group showed increasing frequency of an event that required a secondary prevention indication for LDA during follow-up (Table 2). the persistent adherents had the highest mortality rate (Table 2) and a gradual decrease in non-aspirin antithrombotic treatment during follow-up (Figure S1), mainly due to a gradual increase in non-aspirin antiplatelet treatment (Figure S3).

## Identification of trajectories by presence or not of a secondary prevention indication for LDA use at baseline

We found 4 similar trajectories of adherence among the 4,079 and 7,714 individuals with a baseline secondary prevention indication for LDA use or not,

1 respectively (Figure 3a, 3b). The proportion of persistent adherents was higher for those  
2 with than without a baseline secondary indication for LDA (46.5% vs 31.4%). Moreover,  
3 about half of not-adherents and delayed not-adherents individuals had at least one  
4 reimbursement for a non-aspirin antithrombotic treatment during each assessment  
5 period (Figure S4). For individuals without a secondary indication for LDA, 45.1% were  
6 not adherent to LDA (Figure 3b).

### 7 Predictors of adherence

8 On multinomial logistic regression, the absence of a secondary indication for LDA  
9 use at baseline was the main predictor of being in the not-adherent, delayed not-  
10 adherent or delayed adherent versus persistent adherent group (OR 0.40 [95% CI 0.36-  
11 0.45], 0.53 [0.45-0.63] and 0.74 [0.64-0.85], respectively) (table 3). Moreover, the  
12 probability of being not-adherent was increased with female sex, low socioeconomic  
13 status and polymedication the year before the index event and was decreased with  
14 diabetes, hypertension, dementia,  $\geq 4$  physician consultations in the previous year, and  
15 at least one hospitalization or one cardiologist consultation in the previous 3 months  
16 (Table 3). C-statistics from logistic regression models are shown in table S1.

### 18 Sensitivity analysis

19 In a sensitivity analysis, we also considered a 0.5 cut-off of PDC for good  
20 adherence (Figure S5). As expected, the proportion of individuals was greater in the  
21 persistent adherent group than other groups (44.3% vs. 35.4% in the main model). and

two decreasing adherence group were identified: early decreasing adherence (10.2%) and delayed decreasing adherence (8.3%).

When we excluded all individuals with missing PDC data during follow-up, results were similar to those observed in the first model, so missing data had a low impact on the results.

## **Discussion**

GBTM underlined the presence of 4 distinct profiles of adherence among the French population. Approximately 80% of the population had stable adherence trajectories and were divided between 40% of not-adherents and 37% of persistent adherents throughout the follow-up. Two smaller groups changed their adherence behaviors during follow-up: the delayed not-adherent and the delayed adherent groups, which accounted for 14% and 10% of the study population, respectively.

First, we found a very low rate of persistent adherents during follow-up, as compared with other LDA adherence studies (65% to 92.5%<sup>17,23–27</sup>). However, comparison between our results and other conventional adherence studies is complicated, because most previous studies combined poor adherence and good adherence periods into one average measure. GBTM is advantageous over these conventional methods because it underlines all the clinically relevant periods of adherence that individuals would experience during follow-up. As follows, GBTM underlined the presence of a delayed not-adherent group that showed a gradual decrease in the probability of adherence during follow-up. Some explanations for this apparent decrease in adherence could be physician's decision to interrupt the treatment

1 (reevaluation of the benefit-risk balance, respecting recommendation in the context of  
2 primary prevention...), a switch to another antiplatelet or anticoagulant treatment among  
3 some individuals, the occurrence of major hemorrhagic events which is a  
4 contraindication to maintain the treatment; these possibilities were underlined by the  
5 gradual increase in non-aspirin antithrombotic treatment among 25% of this group  
6 (Figure S1), and the highest rates of hemorrhagic events observed in

7  
8 this group (4.3%) vs other groups. Indeed, this decrease in adherence behavior has  
9 been identified in many adherence trajectories studies independent of the drug under  
10 study<sup>29,30,44–46</sup>, which suggests that a decrease in adherence could also be due in part to  
11 a personal attitude regarding the treatment rather than the treatment itself. Conversely,  
12 9.6% of the study population showed a gradual increase in probability of being adherent  
13 after 15 months of intermediate probability of adherence. Other studies showed  
14 comparable rate: 11.4% of new statin users<sup>29</sup> and 10 % of new antiplatelet users<sup>30</sup>. This  
15 gradual increase may be related to a gradual occurrence of events that advocated  
16 secondary prevention treatment with aspirin and thus also increased the motivation and  
17 awareness among individuals. Accordingly, in 14%, the highest rate among all groups, a  
18 condition developed that required secondary prevention treatment during follow-up.

19 Finally, the not-adherent group accounted for the largest proportion of the study  
20 population (40.2%), which underlines a serious problem of adherence to LDA, which,  
21 apart from the occurrence of a contraindication or a switch to another antithrombotic  
22 therapy, should be taken life-long<sup>15,16</sup>. Previous studies evaluating trajectories of  
23 adherence among new statin and antidiabetic users showed a comparable rate of not  
24 adherents<sup>29,46</sup>, whereas a study of adherence to antihypertensive drugs showed a very

1 low proportion of not adherents (7%)<sup>31</sup>. However, this latter study was not restricted to  
2 new users, among whom discontinuation is frequent in the first year<sup>31</sup>. A possible  
3 explanation for this behavior is the low proportion of individuals with a secondary  
4 prevention indication for LDA (24%), with the uncertain effectiveness of LDA in primary  
5 prevention<sup>4</sup>.

6 Indeed, when we searched for predictors of low adherence to LDA, the absence  
7 of a secondary indication for LDA use was the main predictor of being in the no-  
8 adherent or delayed not-adherent versus persistent adherent group. The probability of  
9 being in the not-adherent group was also increased with female sex, low socioeconomic  
10 status or polymedication, which agreed with other studies<sup>17,20,37,38</sup>, and was decreased  
11 with other covariates that are associated with an increased rate of cardiovascular  
12 diseases. Finally, dementia was also associated with good adherence, which suggests  
13 that these individuals are in an advanced stage and might be relying on caregivers to  
14 administer medications and thus show good adherence behavior<sup>47</sup>.

15 To our knowledge, this is the first study to evaluate dynamic trajectories of  
16 adherence to LDA use among new users, regardless of the indication for use. However,  
17 some limitations to this study should be noted. First, we chose a cutoff of 80% because  
18 it is the most adequate cutoff for cardiovascular medications<sup>38</sup>, however, for LDA use,  
19 this cutoff may be lower, especially because of the possible over-the-counter (OTC)  
20 purchase of this medication. A cutoff of 50% did not greatly change our results,  
21 especially because LDA users are more likely to refill their monthly prescriptions not in  
22 OTC to be reimbursed and also because LDA is frequently associated with other  
23 cardiovascular treatments that could not be purchased as OTC. Moreover, a validation  
24 study of a prescription database showed that unrecorded OTC use had a small impact

on misclassification of LDA use<sup>48</sup>. Second, filling a prescription does not guarantee that the patient actually takes the drug nor the date of the actual consumption; however, a systematic review showed a good association between refill records and adherence<sup>49</sup>. Third, we could not test for primary non-adherence (patients who did not fill their first prescription for LDA), given that no prescription data are available in the French databases. Fourth, we could not investigate all potential LDA adherence predictors, given the lack of information in administrative databases on potential predictors such as patient–physician relationships, social behaviors, lifestyle and education. This was underlined by the poor predictive accuracy of the model (C-statistics=0.6). However, some predictors were identified in this study. Finally, GBTM ignores the intra-correlation between repeated adherence measures in the same individual, which could overestimate the number of identified groups. However, the objective of our study was only exploratory, with no attempt to classify each individual into one class, and GBTM was found to be preferable to some other methods, analyzing developmental trajectories<sup>50</sup>, and summarize longitudinal adherence with visual patterns and more accurately than the conventional approaches<sup>29</sup>.

## Conclusion

This study provides a better understanding of adherence behaviors among new LDA users in France over 3 years and underlines the presence of critical trajectories and time periods when adherence behaviors worsened and that intervention could target to increase adherence. Only one-third of the study population showed persistent adherence behaviors and the situation that most conditioned adherence profiles was the presence of a secondary prevention indication for LDA treatment, which may go in line

with the uncertain efficacy of aspirin in the primary prevention and the contradictory guidelines.

## References

1. WHO | Cardiovascular diseases (CVDs). WHO.  
<http://www.who.int/mediacentre/factsheets/fs317/en/>. Accessed March 13, 2018.
2. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. *Circulation*. 1997;96(8):2751-2753.
3. McNeil JJ, Wolfe R, Woods RL, et al. Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. *N Engl J Med*. 2018;379(16):1509-1518. doi:10.1056/NEJMoa1805819
4. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. *The Lancet*. 2009;373(9678):1849-1860. doi:10.1016/S0140-6736(09)60503-1
5. The ASCEND Study Collaborative Group. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. *N Engl J Med*. August 2018. doi:10.1056/NEJMoa1804988
6. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. *Circulation*. 2002;106(3):388-391.
7. Pignone M, Alberts MJ, Colwell JA, et al. Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes: A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation. *Circulation*. 2010;121(24):2694-2701. doi:10.1161/CIR.0b013e3181e3b133
8. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012) : the fifth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). *Int J Behav Med*. 2012;19(4):403-488. doi:10.1007/s12529-012-9242-5
9. Guirguis-Blake JM, Evans CV, Senger CA, O'Connor EA, Whitlock EP. Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force. *Ann Intern Med*. 2016;164(12):804. doi:10.7326/M15-2113
10. Buse JB, Ginsberg HN, Bakris GL, et al. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus: A Scientific Statement From the American Heart Association and the American Diabetes Association. *Circulation*. 2006;115(1):114-126. doi:10.1161/CIRCULATIONAHA.106.179294
11. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest

- Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 Suppl):e637S-e668S. doi:10.1378/chest.11-2306
12. Chan AT, Ladabaum U. Where Do We Stand With Aspirin for the Prevention of Colorectal Cancer? The USPTF Recommendations. *Gastroenterology*. November 2015. doi:10.1053/j.gastro.2015.11.018
13. Authors/Task Force Members:, Perk J, De Backer G, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) \* Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J*. 2012;33(13):1635-1701. doi:10.1093/eurheartj/ehs092
14. Recommendations - Bon usage des agents plaquettaires - 194fcef638d42481f19a2cd0f91f4fe1.pdf. [http://ansm.sante.fr/var/ansm\\_site/storage/original/application/194fcef638d42481f19a2cd0f91f4fe1.pdf](http://ansm.sante.fr/var/ansm_site/storage/original/application/194fcef638d42481f19a2cd0f91f4fe1.pdf). Accessed March 8, 2016.
15. Smith SC. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National Heart, Lung, and Blood Institute. *Circulation*. 2006;113(19):2363-2372. doi:10.1161/CIRCULATIONAHA.106.174516
16. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol*. 2012;60(24):e44-e164. doi:10.1016/j.jacc.2012.07.013
17. Packard KA, Hilleman DE. Adherence to therapies for secondary prevention of cardiovascular disease: a focus on aspirin. *Cardiovasc Ther*. 2016;34(6):415-422. doi:10.1111/1755-5922.12211
18. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. *Eur Heart J*. 2013;34(38):2940-2948. doi:10.1093/eurheartj/ehs295
19. Biondi-Zoccai GGL, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50 279 patients at risk for coronary artery disease. *Eur Heart J*. 2006;27(22):2667-2674. doi:10.1093/eurheartj/ehl334
20. Duffy D, Kelly E, Trang A, Whellan D, Mills G. Aspirin for Cardioprotection and Strategies to Improve Patient Adherence. *Postgrad Med*. 2014;126(1):18-28. doi:10.3810/pgm.2014.01.2721
21. Sundström J, Hedberg J, Thuresson M, Aarskog P, Johannesen KM, Oldgren J. Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study. *Circulation*. 2017;136(13):1183-1192. doi:10.1161/CIRCULATIONAHA.117.028321

- 1 22. WHO | ADHERENCE TO LONG-TERM THERAPIES: EVIDENCE FOR ACTION. WHO.  
2 [http://www.who.int/chp/knowledge/publications/adherence\\_report/en/](http://www.who.int/chp/knowledge/publications/adherence_report/en/). Accessed March 29,  
3 2018.
- 4 23. Riley RF, Don CW, Aldea GS, et al. Recent Trends in Adherence to Secondary Prevention Guidelines  
5 for Patients Undergoing Coronary Revascularization in Washington State: An Analysis of the Clinical  
6 Outcomes Assessment Program (COAP) Registry. *J Am Heart Assoc.* 2012;1(5):e002733-e002733.  
7 doi:10.1161/JAHA.112.002733
- 8 24. Newby LK. Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary  
9 Artery Disease. *Circulation.* 2006;113(2):203-212. doi:10.1161/CIRCULATIONAHA.105.505636
- 10 25. Tuppin P, Neumann A, Danchin N, et al. Evidence-based pharmacotherapy after myocardial  
11 infarction in France: Adherence-associated factors and relationship with 30-month mortality and  
12 rehospitalization. *Arch Cardiovasc Dis.* 2010;103(6-7):363-375. doi:10.1016/j.acvd.2010.05.003
- 13 26. Simpson E, Beck C, Richard H, Eisenberg MJ, Pilote L. Drug prescriptions after acute myocardial  
14 infarction: Dosage, compliance, and persistence. *Am Heart J.* 2003;145(3):438-444.  
15 doi:10.1067/mhj.2003.143
- 16 27. Moberg C, Naesdal J, Svedberg L-E, Duchateau D, Harte N. Impact of Gastrointestinal Problems on  
17 Adherence to Low-Dose Acetylsalicylic Acid: A Quantitative Study in Patients with Cardiovascular  
18 Risk. *Patient Patient-Centered Outcomes Res.* 2011;4(2):103-113. doi:10.2165/11589200-  
19 000000000-00000
- 20 28. Nagin DS, Odgers CL. Group-Based Trajectory Modeling in Clinical Research. *Annu Rev Clin Psychol.*  
21 2010;6(1):109-138. doi:10.1146/annurev.clinpsy.121208.131413
- 22 29. Franklin JM, Shrank WH, Pakes J, et al. Group-based Trajectory Models: A New Approach to  
23 Classifying and Predicting Long-Term Medication Adherence. *Med Care.* 2013;51(9):789-796.  
24 doi:10.1097/MLR.0b013e3182984c1f
- 25 30. Librero J, Sanf  lix-Gimeno G, Peir   S. Medication Adherence Patterns after Hospitalization for  
26 Coronary Heart Disease. A Population-Based Study Using Electronic Records and Group-Based  
27 Trajectory Models. Ahrens I, ed. *PLOS ONE.* 2016;11(8):e0161381.  
28 doi:10.1371/journal.pone.0161381
- 29 31. Dillon P, Stewart D, Smith SM, Gallagher P, Cousins G. Group-Based Trajectory Models: Assessing  
30 Adherence to Antihypertensive Medication in Older Adults in a Community Pharmacy Setting. *Clin*  
31 *Pharmacol Ther.* 2018;103(6):1052-1060. doi:10.1002/cpt.865
- 32 32. Modi AC. Patterns of Nonadherence to Antiepileptic Drug Therapy in Children With Newly  
33 Diagnosed Epilepsy. *JAMA.* 2011;305(16):1669. doi:10.1001/jama.2011.506
- 34 33. Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merli  re Y. French national health insurance  
35 information system and the permanent beneficiaries sample. *Rev   pid  miologie Sant   Publique.*  
36 2010;58(4):286-290. doi:10.1016/j.respe.2010.04.005
- 37 34. WHOCC - ATC/DDD Index. [http://www.whocc.no/atc\\_ddd\\_index/](http://www.whocc.no/atc_ddd_index/). Accessed December 4, 2015.

- 1 35. WHO | International Classification of Diseases (ICD). <http://www.who.int/classifications/icd/en/>.  
2 Accessed October 30, 2015.
- 3 36. Centers for Medicare & Medicaid Services (2012) Medicare Health & Drug Plan Quality and  
4 Performance Ratings 2013 Part C & Part D Technical Notes Centers for Medicare & Medicaid  
5 Services. [http://www.cms.gov/Medicare/Prescription-Drug-  
6 Coverage/PrescriptionDrugCovGenIn/Downloads/2013C-DPlanRatings102212.zip](http://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovGenIn/Downloads/2013C-DPlanRatings102212.zip). Accessed  
7 September 4, 2015.
- 8 37. Kronish IM, Ye S. Adherence to Cardiovascular Medications: Lessons Learned and Future Directions.  
9 *Prog Cardiovasc Dis*. 2013;55(6):590-600. doi:10.1016/j.pcad.2013.02.001
- 10 38. Ho PM, Bryson CL, Rumsfeld JS. Medication Adherence: Its Importance in Cardiovascular  
11 Outcomes. *Circulation*. 2009;119(23):3028-3035. doi:10.1161/CIRCULATIONAHA.108.768986
- 12 39. ameli.fr - Cartographie des pathologies et des dépenses. [https://www.ameli.fr/l-assurance-  
13 maladie/statistiques-et-publications/etudes-en-sante-publique/cartographie-des-pathologies-et-  
14 des-depenses/index.php](https://www.ameli.fr/l-assurance-maladie/statistiques-et-publications/etudes-en-sante-publique/cartographie-des-pathologies-et-des-depenses/index.php). Accessed November 8, 2018.
- 15 40. Ajrouche A, Estellat C, De Rycke Y, Tubach F. Evaluation of algorithms to identify incident cancer  
16 cases by using French health administrative databases: Cancer incidence in the sniram/egb  
17 databases. *Pharmacoepidemiol Drug Saf*. May 2017. doi:10.1002/pds.4225
- 18 41. JONES BL, NAGIN DS, ROEDER K. A SAS Procedure Based on Mixture Models for Estimating  
19 Developmental Trajectories. *Sociol Methods Res*. 2001;29(3):374-393.  
20 doi:10.1177/0049124101029003005
- 21 42. Jones BL, Nagin DS. Advances in Group-Based Trajectory Modeling and an SAS Procedure for  
22 Estimating Them. *Sociol Methods Res*. 2007;35(4):542-571. doi:10.1177/0049124106292364
- 23 43. Schoot R van de, Sijbrandij M, Winter SD, Depaoli S, Vermunt JK. The GRoLTS-Checklist: Guidelines  
24 for Reporting on Latent Trajectory Studies. *Struct Equ Model Multidiscip J*. 2017;24(3):451-467.  
25 doi:10.1080/10705511.2016.1247646
- 26 44. Mårdby A-C, Schiöler L, Sundell KA, Bjerkeli P, Lesén E, Jönsson AK. Adherence to antidepressants  
27 among women and men described with trajectory models: a Swedish longitudinal study. *Eur J Clin  
28 Pharmacol*. 2016;72(11):1381-1389. doi:10.1007/s00228-016-2106-1
- 29 45. Newman-Casey PA, Blachley T, Lee PP, Heisler M, Farris KB, Stein JD. Patterns of Glaucoma  
30 Medication Adherence over Four Years of Follow-Up. *Ophthalmology*. 2015;122(10):2010-2021.  
31 doi:10.1016/j.ophtha.2015.06.039
- 32 46. Lo-Ciganic W-H, Donohue JM, Jones BL, et al. Trajectories of Diabetes Medication Adherence and  
33 Hospitalization Risk: A Retrospective Cohort Study in a Large State Medicaid Program. *J Gen Intern  
34 Med*. 2016;31(9):1052-1060. doi:10.1007/s11606-016-3747-6
- 35 47. Campbell NL, Boustani MA, Skopelja EN, Gao S, Unverzagt FW, Murray MD. Medication Adherence  
36 in Older Adults With Cognitive Impairment: A Systematic Evidence-Based Review. *Am J Geriatr  
37 Pharmacother*. 2012;10(3):165-177. doi:10.1016/j.amjopharm.2012.04.004

- 1 48. Cea Soriano L, Soriano-Gabarró M, García Rodríguez LA. Validation of low-dose aspirin prescription  
2 data in The Health Improvement Network: how much misclassification due to over-the-counter  
3 use?: Over-the-counter Low-dose Aspirin in THIN. *Pharmacoepidemiol Drug Saf.* 2016;25(4):392-  
4 398. doi:10.1002/pds.3926
- 5 49. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: Methods,  
6 validity, and applications. *J Clin Epidemiol.* 1997;50(1):105-116. doi:10.1016/S0895-4356(96)00268-  
7 5
- 8 50. Twisk J, Hoekstra T. Classifying developmental trajectories over time should be done with great  
9 caution: a comparison between methods. *J Clin Epidemiol.* 2012;65(10):1078-1087.  
10 doi:10.1016/j.jclinepi.2012.04.010

11

12

13

1    **Figure legends**

2    Figure 1: Flow of the population in the study.

3    Figure 2: Trajectories of adherence to low-dose aspirin (LDA) treatment over 36 months  
4    of follow-up in the study population

5    Figure 3: Trajectories of adherence to LDA treatment over 36 months of follow-up in the  
6    study population by presence or not of a secondary prevention indication for LDA

7

8

9

10

11

12

13

14

15

16

17

## Tables

Table 1: Characteristics of the study population by adherence trajectory.

|                                                                                | Not-adherent<br>group | Delayed<br>not-adherent<br>group | Delayed<br>adherent group | Persistent<br>adherent<br>group | Total            |
|--------------------------------------------------------------------------------|-----------------------|----------------------------------|---------------------------|---------------------------------|------------------|
|                                                                                | N=4737                | N=1601                           | N=1137                    | N=4318                          | N=11793          |
| <b>Baseline patient-related factors</b>                                        |                       |                                  |                           |                                 |                  |
| Age, median (IQR)                                                              | 67.0 [60.0-77.0]      | 71.0 [62.0-80.0]                 | 69.0 [61.0-78.0]          | 71.0 [62.0-80.0]                | 69.0 [61.0-79.0] |
| Women, N (%)                                                                   | 2563 (54.1)           | 811 (50.7)                       | 524 (46.1)                | 2042 (47.3)                     | 5940 (50.4)      |
| Number of physician visits in the year before the index date, median (IQR)     | 11.0 [7.0-18.0]       | 12.0 [7.0-18.0]                  | 12.0 [7.0-17.0]           | 12.0 [7.0-18.0]                 | 12.0 [7.0-18.0]  |
| Number of distinct ATC classes in the year before the index date, median (IQR) | 10.0 [7.0-14.0]       | 10.0 [7.0-14.0]                  | 10.0 [7.0-14.0]           | 11.0 [7.0-14.0]                 | 10.0 [7.0-14.0]  |

|                                                                                                 | Not-adherent<br>group | Delayed<br>not-adherent<br>group | Delayed<br>adherent group | Persistent<br>adherent<br>group | Total       |
|-------------------------------------------------------------------------------------------------|-----------------------|----------------------------------|---------------------------|---------------------------------|-------------|
|                                                                                                 | N=4737                | N=1601                           | N=1137                    | N=4318                          | N=11793     |
| Hospitalization in the year<br>before the index date, N (%)                                     | 446 (39.2)            | 1837 (38.8)                      | 769 (48.0)                | 2310 (53.5)                     | 5362 (45.5) |
| Hospitalization or cardiologist<br>consultation in the 3 months<br>before the index date, N (%) | 1910 (40.3)           | 869 (54.3)                       | 505 (44.4)                | 2554 (59.1)                     | 5838 (49.5) |
| Low socioeconomic status*,<br>N (%)                                                             | 335 (7.1)             | 93 (5.8)                         | 73 (6.4)                  | 180 (4.2)                       | 681 (5.8)   |
| <b>Indication for LDA as<br/>secondary prevention, N<br/>(%)</b>                                | 1173 (24.8)           | 607 (37.9)                       | 317 (27.9)                | 1982 (45.9)                     | 4079 (34.6) |
| Coronary heart disease †                                                                        | 523 (11.0)            | 299 (18.7)                       | 153 (13.5)                | 1119 (25.9)                     | 2094 (17.8) |
| Stroke or transient ischemic                                                                    | 206 (4.3)             | 144 (9.0)                        | 48 (4.2)                  | 415 (9.6)                       | 813 (6.9)   |

|                                                             | <b>Not-adherent<br/>group</b> | <b>Delayed<br/>not-adherent<br/>group</b> | <b>Delayed<br/>adherent group</b> | <b>Persistent<br/>adherent<br/>group</b> | <b>Total</b>   |
|-------------------------------------------------------------|-------------------------------|-------------------------------------------|-----------------------------------|------------------------------------------|----------------|
|                                                             | <b>N=4737</b>                 | <b>N=1601</b>                             | <b>N=1137</b>                     | <b>N=4318</b>                            | <b>N=11793</b> |
| attack                                                      |                               |                                           |                                   |                                          |                |
| Peripheral artery disease                                   | 511 (10.8)                    | 222 (13.9)                                | 142 (12.5)                        | 718 (16.6)                               | 1593 (13.5)    |
| Atrial fibrillation                                         | 378 (8.0)                     | 171 (10.7)                                | 80 (7.0)                          | 448 (10.4)                               | 1077 (9.1)     |
| Bioprosthetic or mechanical<br>valvular replacement surgery | 21 (0.4)                      | 10 (0.6)                                  | 7 (0.6)                           | 42 (1.0)                                 | 80 (0.7)       |
| <b>Other cardiovascular risk factors, N (%)</b>             |                               |                                           |                                   |                                          |                |
| Diabetes                                                    | 1020 (21.5)                   | 444 (27.7)                                | 364 (32.0)                        | 1373 (31.8)                              | 3201 (27.1)    |
| Hypertension                                                | 1427 (30.1)                   | 446 (27.9)                                | 337 (29.6)                        | 1055 (24.4)                              | 3265 (27.7)    |
| Dyslipidemia                                                | 1004 (21.2)                   | 288 (18.0)                                | 227 (20.0)                        | 621 (14.4)                               | 2140 (18.1)    |
| Morbid obesity                                              | 363 (7.66)                    | 363 (7.7)                                 | 168 (10.5)                        | 113 (9.9)                                | 460 (10.7)     |
| Heavy alcoholism                                            | 199 (4.2)                     | 199 (4.2)                                 | 65 (4.1)                          | 60 (5.3)                                 | 186 (4.3)      |
| Heavy smoking                                               | 421 (8.89)                    | 421 (8.9)                                 | 169 (10.6)                        | 97 (8.5)                                 | 543 (12.6)     |

|                                   | <b>Not-adherent<br/>group</b> | <b>Delayed<br/>not-adherent<br/>group</b> | <b>Delayed<br/>adherent group</b> | <b>Persistent<br/>adherent<br/>group</b> | <b>Total</b>   |
|-----------------------------------|-------------------------------|-------------------------------------------|-----------------------------------|------------------------------------------|----------------|
|                                   | <b>N=4737</b>                 | <b>N=1601</b>                             | <b>N=1137</b>                     | <b>N=4318</b>                            | <b>N=11793</b> |
| <b>Other comorbidities, N (%)</b> |                               |                                           |                                   |                                          |                |
| Psychiatric disorder              | 303 (6.4)                     | 121 (7.6)                                 | 87 (7.7)                          | 298 (6.9)                                | 809 (6.9)      |
| Dementia                          | 146 (3.1)                     | 85 (5.3)                                  | 37 (3.3)                          | 200 (4.6)                                | 468 (4.0)      |
| Endstage chronic renal failure    | 66 (1.4)                      | 24 (1.5)                                  | 10 (0.9)                          | 65 (1.5)                                 | 165 (1.4)      |
| Cancer                            | 725 (15.3)                    | 241 (15.1)                                | 156 (13.7)                        | 706 (16.4)                               | 1828 (15.5)    |
| Major haemorrhage                 | 125 (2.6)                     | 52 (3.2)                                  | 21 (1.8)                          | 112 (2.6)                                | 310 (2.6)      |

\*defined by complementary universal health coverage

† includes coronary artery disease, unstable angina, myocardial infarction, undergoing coronary artery bypass grafting or percutaneous coronary intervention

IQR, interquartile range

Table 2: Occurrence of events during follow-up by adherence group.

| <b>Events</b>                                                     | <b>Not-<br/>adherent<br/>group<br/><br/>N=4737</b> | <b>Delayed<br/>not-<br/>adherent<br/>group<br/><br/>N=1601</b> | <b>Delayed<br/>adherent<br/>group<br/><br/>N=1137</b> | <b>Persistent<br/>adherent<br/>group<br/><br/>N=4318</b> | <b>Total<br/><br/>N=11793</b> | <b>P value</b> |
|-------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------------------|-------------------------------------------------------|----------------------------------------------------------|-------------------------------|----------------|
| <b>Reason for end of follow-up, N (%)</b>                         |                                                    |                                                                |                                                       |                                                          |                               |                |
| Exit from the database                                            | 38 (0.8)                                           | 6 (0.4)                                                        | 6 (0.5)                                               | 31 (0.7)                                                 | 81 (0.7)                      |                |
| Death                                                             | 508 (10.7)                                         | 169 (10.6)                                                     | 85 (7.5)                                              | 531 (12.3)                                               | 1293 (11.0)                   |                |
| <b>Events during follow-up, N (%)</b>                             |                                                    |                                                                |                                                       |                                                          |                               |                |
| First occurrence of a secondary prevention indication for LDA use | 349 (7.4)                                          | 201 (12.6)                                                     | 169 (14.9)                                            | 456 (10.6)                                               | 1175 (10.0)                   | <0.0001        |
| Acute coronary event                                              | 25 (0.5)                                           | 28 (1.8)                                                       | 25 (2.2)                                              | 97 (2.3)                                                 | 175 (1.5)                     | <0.0001        |
| Acute stroke or transient ischemic attack                         | 68 (1.4)                                           | 40 (2.5)                                                       | 43 (3.8)                                              | 86 (2.0)                                                 | 237 (2.0)                     | <0.0001        |
| Major haemorrhage*                                                | 132 (2.8)                                          | 69 (4.3)                                                       | 45 (4.0)                                              | 132 (3.1)                                                | 378 (3.2)                     | 0.0107         |

\*Only major hemorrhagic events that required hospitalization could be identified in the database.

Table 3: Multivariate analysis of predictors of adherence trajectories during follow-up.

|                                                                            | Not-adherent<br>vs persistent<br>adherent group |                    | Delayed<br>vs persistent<br>adherent group |             | Delayed<br>not-adherent<br>vs persistent<br>adherent group |             |         |
|----------------------------------------------------------------------------|-------------------------------------------------|--------------------|--------------------------------------------|-------------|------------------------------------------------------------|-------------|---------|
|                                                                            | OR                                              | 95% CI             | OR                                         | 95% CI      | OR                                                         | 95% CI      | P value |
| <b>Patient-related factors</b>                                             |                                                 |                    |                                            |             |                                                            |             |         |
| Female sex                                                                 | <b>1.18</b>                                     | <b>[1.08-1.29]</b> | 1.10                                       | [0.98-1.24] | 0.87                                                       | [0.76-1.00] | <0.0001 |
| Low socioeconomic status*                                                  | <b>1.78</b>                                     | <b>[1.47-2.16]</b> | 1.46                                       | [1.12-1.89] | 1.55                                                       | [1.17-2.05] | <0.0001 |
| <i>Distinct ATC class deliveries in<br/>the year before the index date</i> |                                                 |                    |                                            |             |                                                            |             |         |
| 11-20 †                                                                    | 1.07                                            | [0.96-1.18]        | 1.04                                       | [0.91-1.20] | 0.86                                                       | [0.73-1.00] | <.0001  |
| ≥ 21 †                                                                     | <b>1.65</b>                                     | <b>[1.33-2.04]</b> | 0.94                                       | [0.69-1.28] | 1.00                                                       | [0.71-1.42] |         |
| <i>Physician consultations in the<br/>year before the index date</i>       |                                                 |                    |                                            |             |                                                            |             |         |
| 4-6 ‡                                                                      | <b>0.71</b>                                     | <b>[0.59-0.85]</b> | 0.65                                       | [0.51-0.83] | 0.89                                                       | [0.66-1.20] | 0.0006  |
| 7-12 ‡                                                                     | <b>0.77</b>                                     | <b>[0.65-0.92]</b> | 0.75                                       | [0.60-0.93] | 1.16                                                       | [0.90-1.52] |         |

|                                                                                    |             |                    |      |             |      |             |        |
|------------------------------------------------------------------------------------|-------------|--------------------|------|-------------|------|-------------|--------|
| ≥ 13 ‡                                                                             | <b>0.80</b> | <b>[0.67-0.95]</b> | 0.73 | [0.58-0.92] | 1.20 | [0.91-1.59] |        |
| Hospitalization or cardiologist consultation in the 3 months before the index date | <b>0.59</b> | <b>[0.54-0.65]</b> | 0.91 | [0.80-1.04] | 0.66 | [0.58-0.77] | <.0001 |
| <b>Indication for LDA</b>                                                          |             |                    |      |             |      |             |        |
| Secondary prevention indication for LDA                                            | <b>0.39</b> | <b>[0.35-0.44]</b> | 0.72 | [0.63-0.83] | 0.50 | [0.43-0.59] | <.0001 |
| <b>Other cardiovascular risk factors</b>                                           |             |                    |      |             |      |             |        |
| Diabetes                                                                           | <b>0.44</b> | <b>[0.40-0.50]</b> | 0.79 | [0.68-0.91] | 0.91 | [0.77-1.08] | <.0001 |
| Hypertension                                                                       | <b>0.66</b> | <b>[0.59-0.74]</b> | 0.94 | [0.80-1.10] | 0.95 | [0.79-1.13] | <.0001 |
| <b>Other comorbidities</b>                                                         |             |                    |      |             |      |             |        |
| Dementia                                                                           | <b>0.73</b> | <b>[0.58-0.91]</b> | 1.19 | [0.92-1.55] | 0.83 | [0.58-1.19] | 0.0028 |

Only variables significant at p<0.05 were included in the multivariate analysis.

\* defined as complementary universal health coverage

†Number of distinct ATC classes delivered per year was classified in 3 classes: ≤ 10, 11-20, ≥ 21

‡Number of consultations per year was classified in 4 classes: ≤ 3, 4-6, 7-12, ≥ 13

## Figures

Figure 1: Flow of the population in the study.






Figure 2: Trajectories of adherence to low-dose aspirin (LDA) treatment over 36 months of follow-up in the study population



\* 95% confidence intervals are represented by the gray band around each gray line


Figure 3: Trajectories of adherence to LDA treatment over 36 months of follow-up in the study population by presence or not of a secondary prevention indication for LDA

Figure 3.a: Trajectories of adherence to LDA treatment over 36 months of follow-up among those with a secondary prevention indication for LDA



\* 95% confidence intervals are represented by the gray band around each gray line

Figure 3.b: Trajectories of adherence to LDA treatment over 36 months of follow-up among those without a secondary prevention indication for LDA



\* 95% confidence intervals are represented by the gray band around each gray line